In vitro activity of pyrvinium pamoate against Entamoeba histolytica and Giardia intestinalis using radiolabelled thymidine incorporation and an SYBR Green I-based fluorescence assay

Objectives To assess the in vitro activity of the FDA-approved antihelminthic drug pyrvinium pamoate against Entamoeba histolytica and Giardia intestinalis. Methods A head-to-head comparison of a standard radiolabelled thymidine incorporation assay and the SYBR Green I-based fluorescence assay for d...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2009-10, Vol.64 (4), p.751-754
Main Authors: Downey, Autumn S., Graczyk, Thaddeus K., Sullivan, David J.
Format: Article
Language:English
Subjects:
Animals
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiprotozoal Agents - pharmacology
Biological and medical sciences
Clinical trials
Comparative studies
DNA - metabolism
DNA Replication - drug effects
drug
drug assay
Entamoeba histolytica
Entamoeba histolytica - drug effects
Gastroenterology
Giardia
Giardia intestinalis
Giardia lamblia - drug effects
Inhibitory Concentration 50
Medical sciences
Organic Chemicals - metabolism
Original Research
Parasites
Parasitic Sensitivity Tests - methods
Pharmacology
Pharmacology. Drug treatments
protozoan
Pyrvinium Compounds - pharmacology
Thymidine - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives To assess the in vitro activity of the FDA-approved antihelminthic drug pyrvinium pamoate against Entamoeba histolytica and Giardia intestinalis. Methods A head-to-head comparison of a standard radiolabelled thymidine incorporation assay and the SYBR Green I-based fluorescence assay for determination of in vitro inhibition by pyrvinium and metronidazole was performed. Results The 50% inhibitory concentration (IC50) for treatment of E. histolytica with pyrvinium was 4–5 µM for both assays compared with 1–2 µM for metronidazole. For pyrvinium treatment of G. intestinalis, an IC50 of ∼12 µM was determined by the radiolabelled thymidine assay alone, with maximum inhibition around 60%. In contrast, the IC50 for metronidazole treatment using this assay was ∼2 µM. Conclusions Pyrvinium is a potential gut lumen agent for treatment of intestinal amoebiasis, but possibly not for giardiasis. SYBR Green I is an alternative screening method for E. histolytica, but not G. intestinalis.
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dkp296